Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
South America Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-like peptide-1 (GLP-1), Pens and Needles, and Others)
- Report Code : BMIRE00027250
- Pages : 177
The insulin market in SAM is expected to grow from US$ 4,868.81 million in 2022 to US$ 8,930.46 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.
Rapid Technological Developments in Insulin Delivery Devices by Major Players
Products with advanced insulin technology with more effective benefits are a major requirement in the treatment of diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing across region, the demand for more advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.
A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:
• In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial initiated in China.
• In May 2021, Bigfoot Biomedical received 510(k) clearance by USFDA for its Bigfoot Unity Diabetes Management System, which features connected smart pen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.
Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the SAM insulin market.
Market Overview
The SAM insulin market is segmented into Argentina, Brazil, and the Rest of SAM. The market growth is attributed to the increasing occurrence of diabetes (both type I and type II) in the region. Furthermore, regulatory frameworks favoring the operations of insulin manufacturers encourage various multinational companies to establish their production units in SAM countries. According to International Diabetes Federation, 33 million adults (20–79 years) were living with diabetes in SAM in 2021. The figure is estimated to rise to 40 million by 2030 and 49 million by 2045. Per the report, 15.7 million adults are living with diabetes in Brazil, representing 1 in 10 adults. The increasing incidence of diabetes is leading to the degradation of the quality of life of patients. According an article published in the Annals of Global Health, in November 2019, the diabetes epidemic affects most countries across the world and has alarming infection rates in Latin American countries. ~12 million individuals have diabetes in Brazil, with the current prevalence ranging from 6.3% to 13.5%. The rising diabetes prevalence has further translated into a 60% growth in the related risk ratio for cardiovascular diseases associated with diabetes.
Exhibit: SAM Insulin Market Revenue and Forecast to 2028 (US$ Million)
SAM Insulin Market Segmentation
The SAM insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.
Based on long acting insulin, the SAM insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022. Based on short acting insulin and traditional human insulin, the SAM insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
Based on concentrated insulin and combination insulin, the SAM insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022. Based on biosimilar insulin, the SAM insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022. Based on country, the market is segmented into Brazil, Argentina, and Rest of SAM. Rest of SAM dominated the market share in 2022. Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Insulin Market – By Type
1.3.2 SAM Insulin Market – By Country
2. SAM Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Insulin Market – Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.2.1 Expert Opinion
5. SAM Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– SAM Analysis
6.1 SAM Insulin Market Revenue Forecast and Analysis
7. SAM Insulin Market Analysis – By Type
7.1 Overview
7.2 SAM Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. SAM Insulin Market – Country Analysis
8.1 Overview
8.1.1 SAM Insulin Market Revenue and Forecast to 2028, by Country (%)
8.1.1.1 Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.1.1 Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.1.2 Brazil: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.2 Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.2.1 Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.2.2 Argentina: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.3 Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.3.1 Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.1.1.3.2 Rest of SAM: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.3.2.1 Rest of SAM: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.2 Rest of SAM: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.3 Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.4 Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.5 Rest of SAM: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
9. SAM Insulin Market–Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 GlaxoSmithKline plc.
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Sanofi
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Pfizer Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Merck & Co., Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
LIST OF TABLES
Table 1. SAM Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)
Table 2. Brazil: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 4. Brazil: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 6. Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Argentina: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 10. Argentina: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 11. Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 12. Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of SAM: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of SAM: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 16. Rest of SAM: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of SAM: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments in the Insulin Market
Table 21. Inorganic Developments in the Insulin Market
Table 22. Glossary of Terms, SAM Insulin Market
LIST OF FIGURES
Figure 1. SAM Insulin Market Segmentation
Figure 2. SAM Insulin Market Segmentation, By Country
Figure 3. SAM Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Rest of SAM Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. South America PEST Analysis
Figure 8. Expert Opinion
Figure 9. SAM Insulin Market Impact Analysis of Drivers and Restraints
Figure 10. SAM Insulin Market– Revenue Forecast and Analysis
Figure 11. SAM Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 12. SAM Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. SAM Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. SAM Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. SAM Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. SAM Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. SAM Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. SAM Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. SAM Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. SAM Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. SAM Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. SAM Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. SAM Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. SAM Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. SAM Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. SAM NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. SAM Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. SAM Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. SAM Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. SAM Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. SAM Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. SAM Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. SAM Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. SAM Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. SAM Insulin Market Revenue Overview, By Country (2021) (US$ Mn)
Figure 39. SAM Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 40. Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 42. Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM insulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the SAM insulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – South America Insulin Market
● Biocon
● Eli Lilly and Company
● GlaxoSmithKline plc.
● Merck & Co., Inc.
● Novo Nordisk A/S
● Pfizer Inc.
● Sanofi
● Tonghua Dongbao Pharmaceutical Co., Ltd.
● Wockhardt
At 10.6% CAGR, the South America Insulin Market is speculated to be worth US$ 8,930.46 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the SAM insulin market was valued at US$ 4,868.81 million in 2022 and is expected to reach US$ 8,930.46 million by 2028, registering an annual growth rate of 10.6% from 2022 to 2028. Increase in incidence of diabetes and rapid technological developments in insulin delivery devices by major players are the critical factors attributed to the market expansion.
Diabetes is a life-threatening chronic disease with no specialized cure. It is mainly caused by the body’s incapacity to produce or effectively utilize the hormone insulin. This incapacity prevents the body from adequately regulating blood glucose levels. Incidence and prevalence of diabetes are rapidly increasing across the region. Type 2 diabetes is the most prevalent form of diabetes and has grown alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to the International Diabetes Federation (IDF), approximately 537 million people were living with diabetes in 2021, and it is expected to reach 643 million by 2030 and 783 million by 2045 across the region. Diabetes can lead to complications in many body parts and increase the risk of premature death. Primary complications include heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Patients who have diabetes require frequent monitoring and external administration of insulin. Thus, the rising prevalence of diabetes is driving the insulin market.
On the contrary, risks associated with insulin delivery devices hurdles the growth of SAM insulin market.
Based on type, the SAM insulin market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment held 27.3% market share in 2022, amassing US$ 1,331.15 million. It is projected to garner US$ 2,446.94 million by 2028 to expand at 10.7% CAGR during 2022–2028.
Based on long acting insulin, the SAM insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment held 50.7% market share in 2022, amassing US$ 674.48 million. It is projected to garner US$ 1,264.61 million by 2028 to expand at 11.0% CAGR during 2022–2028. Based on rapid acting insulins the SAM insulin market is sub-segmented into novolog, humalog, admelog, and others. The humalog segment held 50.4% market share in 2022, amassing US$ 331.82 million. It is projected to garner US$ 609.64 million by 2028 to expand at 10.7% CAGR during 2022–2028. Based on short acting insulin and traditional human insulin, the SAM insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held 51.9% market share in 2022, amassing US$ 288.30 million. It is projected to garner US$ 480.25 million by 2028 to expand at 8.9% CAGR during 2022–2028. Based on concentrated insulin and combination insulin, the SAM insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held 49.6% market share in 2022, amassing US$ 145.12 million. It is projected to garner US$ 282.02 million by 2028 to expand at 11.7% CAGR during 2022–2028. Based on biosimilar insulin, the SAM insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held 53.2% market share in 2022, amassing US$ 359.59 million. It is projected to garner US$ 754.65 million by 2028 to expand at 13.2% CAGR during 2022–2028. Based on country, the SAM insulin market is segmented into Brazil, Argentina, and Rest of SAM. Our regional analysis states that Rest of SAM captured 38.0% market share in 2022. It was assessed at US$ 1,851.61 million in 2022 and is likely to hit US$ 3,331.96 million by 2028, exhibiting a CAGR of 10.3% during the forecast period. Key players dominating the SAM insulin market are Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt among others.
In 2021, Viatris launched a non-interchangeable Semglee in 2020 at a WAC price of $99, marking a steep discount off Lantus’ WAC of $284. In 2020, Pfizer showcased Phase I data from a study assessing PF-06882961, an oral small molecule glucagon-like peptide – 1 receptor (GLP-1 R) agonist in type 2 diabetes patients that showed significant promise in the reduction of glucose levels and body weight.
Related Reports
- $3,000.00 – $5,000.00
